CONCORDBIO — Concord Biotech Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapFalling Star

Annual income statement for Concord Biotech, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	PROSPECTUS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	5,123	6,169	7,129	8,532	10,169
Cost of Revenue
Gross Profit	3,451	4,655	4,773	5,753	6,828
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	3,183	3,147	4,893	5,621	6,389
Operating Profit	1,940	3,022	2,236	2,911	3,780
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	2,136	3,127	2,375	3,220	4,126
Provision for Income Taxes
Net Income After Taxes	1,691	2,349	1,749	2,401	3,081
Net Income Before Extraordinary Items
Net Income	1,691	2,349	1,749	2,401	3,081
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	1,691	2,349	1,749	2,401	3,081
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	16.2	22.5	16.7	23	29.4
Dividends per Share